Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - May 2012

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Etanercept (Enbrel®) has been accepted for restricted use the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years. The restriction applies to disease severity and intolerance or inadequate response to other treatments.

Etanercept (Enbrel®) has also been accepted for restricted use in the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years. The restriction applies to use in specialist rheumatology services when there has been intolerance or inadequate response to methotrexate.

Insulin detemir (Levemir®) has been accepted for restricted use in the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. The restriction applies to patients unable to achieve good glycaemic control with established insulins. The SMC note that this advice has been issued previously with a lower age limit of 6 years old.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - May 2012' on Email Share 'SMC Update - May 2012' on Delicious Share 'SMC Update - May 2012' on Digg Share 'SMC Update - May 2012' on Facebook Share 'SMC Update - May 2012' on Google+ Share 'SMC Update - May 2012' on reddit Share 'SMC Update - May 2012' on StumbleUpon Share 'SMC Update - May 2012' on Twitter

atomic-wealth

No Comments to “SMC Update - May 2012”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer